tirzepatide for kidney disease (Zepbound) showed improved function in obese patients with both chronic kidney and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https Weight Loss/Diabetic Drug Tirzepatide Slashes

"Our study now shows that if you are in a subgroup of long COVID patients who have autoantibodies circulating in your body

Patients participate exclusively on a direct-pay basis, ensuring prices stay low and care stays accessible

Important caveat: the 27.7% figure reflects a subgroup of early responders, not every patient

All treated biofilms were then incubated for 24 h at 37C in a static incubator

Aided by a grant from the Medical Research Council of Canada, he established a laboratory to explore the hormones and physiology of the gastrointestinal system

While overall AE rates were generally comparable between treatment arms, GI AEs were notably more frequent among participants treated with semaglutide, occurring in 41.9%84.1% of cases, compared with 26.1%63.2% in placebo groups